WARF: P01150US

  • Assigned to WARF as biological material.

Eight Hybridoma Cell Lines Producing Monoclonal Antibodies Against La Crosse Encephalitis Virus


Thomas Yuill

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in eight lines of hybridomas that are specific for G1, G2 or both.
OVERVIEWLa Crosse virus is an etiologic agent for childhood encephalitis in North America. Structurally, the nucleocapsid of this virus is enclosed by a host-derived lipid envelope holding two virion glycoproteins, G1 and G2. These proteins are believed to be responsible for attachment of the virus to cells. Although several researchers had been successful at producing specific monoclonal antibodies against the larger G1, production of a monoclonal antibody directed against the G2 viral protein has not been reported.
THE INVENTIONUW-Madison researchers have now produced eight lines of hybridomas, one of which is specific for G1, five of which are specific for G2, and two of which recognize both G1 and G2. Frozen stocks are available at UW-Madison.
  • Currently used for diagnostic assays for the California group of encephalitis virus by the Centers for Disease Control and Prevention
  • Specifically recognizes G1, G2 or both
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.